LYTIR

Insider · SEC Form 4 · Director, 10% Owner

ORBIMED ADVISORS LLC

In the 12 months to Nov 19, 2026, on the open market: bought $135.4M of BRVE, ETRA, WWB and 4 more; sold $60.8M of ELVN, SION. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $135.4M in total; Insider sales: $60.8M in total.Jun: Insider sales $57.0MJul: Insider purchases $15.0MJul: Insider sales $3.9MAug: Insider purchases $44.9MSep: Insider purchases $36.1MNov: Insider purchases $39.3MDecJanFebMarAprMayJunJulAugSepOctNov$44.9M$57.0M
Insider purchases above the line: $135.4MInsider sales below: $60.8M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. WWBBought: WINDWARD BIO GROUP AG Nov 16, 2026 1,176,471 shares filed Nov 18, 2026 1,708,103 shares held indirectly after, as filed filing $20.0M
  2. ETRABought: Electra Therapeutics, Inc. Nov 10, 2026 22,700 shares filed Nov 10, 2026 2 transactions filing $192K
  3. ETRABought: Electra Therapeutics, Inc. Nov 9, 2026 20,000 shares filed Nov 10, 2026 2 transactions filing $165K
  4. ETRABought: Electra Therapeutics, Inc. Nov 6, 2026 49,416 shares filed Nov 10, 2026 2 transactions filing $388K
  5. ETRABought: Electra Therapeutics, Inc. Nov 5, 2026 156,091 shares filed Nov 5, 2026 2 transactions filing $1.1M
  6. ETRABought: Electra Therapeutics, Inc. Nov 4, 2026 71,367 shares filed Nov 5, 2026 4 transactions filing $537K
  7. ETRABought: Electra Therapeutics, Inc. Nov 3, 2026 245,113 shares filed Nov 5, 2026 4 transactions filing $1.9M
  8. ASPEBought: Aspen Neuroscience, Inc. Nov 2, 2026 1,000,000 shares filed Nov 4, 2026 3,589,132 shares held indirectly after, as filed filing $15.0M
  9. ADRXBought: ADARx Pharmaceuticals, Inc. Sep 28, 2026 950,000 shares filed Sep 30, 2026 3 transactions filing $16.1M
  10. ETRABought: Electra Therapeutics, Inc. Sep 21, 2026 1,333,333 shares filed Sep 23, 2026 2 transactions filing $20.0M
  11. BLSMBought: BlossomHill Therapeutics, Inc. Aug 10, 2026 625,000 shares filed Aug 12, 2026 2,714,279 shares held indirectly after, as filed filing $10.0M
  12. BRVEBought: Braveheart Bio, Inc. Aug 7, 2026 1,940,000 shares filed Aug 11, 2026 2 transactions filing $34.9M
  13. SCTXBought: Scribe Therapeutics, Inc. Jul 27, 2026 1,000,000 shares filed Jul 29, 2026 1,348,825 shares held indirectly after, as filed filing $15.0M
  14. SIONSold: Sionna Therapeutics, Inc. Jul 7, 2026 85,918 shares filed Jul 9, 2026 2,469,959 shares held indirectly after, as filed 10b5-1 plan filing $3.9M
  15. SIONSold: Sionna Therapeutics, Inc. Jun 30, 2026 115,844 shares filed Jul 2, 2026 2,555,877 shares held indirectly after, as filed 10b5-1 plan filing $5.3M
  16. ELVNSold: Enliven Therapeutics, Inc. Jun 22, 2026 860,123 shares filed Jun 24, 2026 4 transactions filing $39.0M
  17. ELVNSold: Enliven Therapeutics, Inc. Jun 15, 2026 281,408 shares filed Jun 17, 2026 2 transactions filing $12.7M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. ASPEORBIMED ADVISORS LLC filed Nov 6, 2026 Schedule 13D may seek influence 3,589,132 shares issuer: Aspen Neuroscience, Inc. filing 12.3%
  2. AVBPORBIMED ADVISORS LLC filed Oct 8, 2026 Schedule 13D/A may seek influence 2,875,962 shares issuer: ArriVent BioPharma, Inc. filing 5.8%
  3. ADRXORBIMED ADVISORS LLC filed Oct 2, 2026 Schedule 13D may seek influence 14,913,764 shares issuer: ADARx Pharmaceuticals, Inc. filing 14%
  4. ETRAORBIMED ADVISORS LLC filed Sep 25, 2026 Schedule 13D may seek influence 6,885,170 shares issuer: Electra Therapeutics, Inc. filing 11%
  5. BRVEORBIMED ADVISORS LLC filed Sep 10, 2026 Schedule 13D/A may seek influence 12,175,159 shares issuer: Braveheart Bio, Inc. filing 13.5%
  6. BRVEORBIMED ADVISORS LLC filed Aug 18, 2026 Schedule 13D may seek influence 12,175,159 shares issuer: Braveheart Bio, Inc. filing 17.2%
  7. BLSMORBIMED ADVISORS LLC filed Aug 18, 2026 Schedule 13D may seek influence 2,714,279 shares issuer: BlossomHill Therapeutics, Inc. filing 8.9%
  8. WHWKOrbiMed Advisors LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Whitehawk Therapeutics, Inc. filing 7.3%
  9. FBRXORBIMED ADVISORS LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Forte Biosciences, Inc. filing 6.2%
  10. IMUXOrbiMed Advisors LLC filed Aug 14, 2026 Schedule 13G passive issuer: Immunic, Inc. filing 5.3%
  11. SPRBOrbiMed Advisors LLC filed Aug 14, 2026 Schedule 13G passive issuer: Spruce Biosciences, Inc. filing 4.8%
  12. NPCEOrbiMed Advisors LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: NeuroPace, Inc. filing 4.4%
  13. LXEOOrbiMed Advisors LLC filed Aug 14, 2026 Schedule 13G passive issuer: Lexeo Therapeutics, Inc. filing 4.1%
  14. VTGNORBIMED ADVISORS LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Vistagen Therapeutics, Inc. filing 0%
  15. MBXORBIMED ADVISORS LLC filed Aug 10, 2026 Schedule 13D/A may seek influence 3,074,853 shares issuer: MBX Biosciences, Inc. filing 6.4%
  16. VYNEORBIMED ADVISORS LLC filed Aug 5, 2026 Schedule 13D may seek influence 266,306 shares issuer: Yarrow Bioscience, Inc. filing 9.97%
  17. SCTXORBIMED ADVISORS LLC filed Jul 29, 2026 Schedule 13D may seek influence 1,348,825 shares issuer: Scribe Therapeutics, Inc. filing 7.2%
  18. QTTBORBIMED ADVISORS LLC filed Jul 20, 2026 Schedule 13D/A may seek influence 4,127,987 shares issuer: Q32 Bio Inc. filing 13.9%
  19. ELVNORBIMED ADVISORS LLC filed Jun 24, 2026 Schedule 13D/A may seek influence 6,774,507 shares issuer: Enliven Therapeutics, Inc. filing 9.5%
  20. ELVNORBIMED ADVISORS LLC filed Jun 17, 2026 Schedule 13D/A may seek influence 7,634,630 shares issuer: Enliven Therapeutics, Inc. filing 10.93%
  21. STTKORBIMED ADVISORS LLC filed Jun 15, 2026 Schedule 13D/A may seek influence 9,021,127 shares issuer: Shattuck Labs, Inc. filing 9.99%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • ADRX: conversion (code C), 8 entries, Sep 28, 2026
  • ASPE: conversion (code C), 5 entries, Nov 2, 2026
  • ETRA: conversion (code C), 4 entries, Sep 21, 2026
  • BLSM: conversion (code C), 2 entries, Aug 10, 2026
  • WWB: conversion (code C), 2 entries, Nov 16, 2026
  • BRVE: conversion (code C), 1 entry, Aug 7, 2026
  • SCTX: conversion (code C), 1 entry, Jul 27, 2026
  • WWB: shares withheld for tax or exercise price (code F), 1 entry, Nov 16, 2026
  • WWB: option exercise or conversion (code M), 1 entry, Nov 16, 2026
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.
Code F
Shares paid to, or withheld by, the company to cover an exercise price or the tax due on an award.
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.